Advice
following an abbreviated submission
vibegron (Obgemsa®) is accepted for use within NHSScotland.
Indication under review: symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.
Vibegron offers an additional treatment choice in the therapeutic class of beta-3 adrenergic receptor agonists in this setting.
Download detailed advice275KB (PDF)
Medicine details
- Medicine name:
- vibegron (Obgemsa)
- SMC ID:
- SMC2696
- Indication:
Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.
- Pharmaceutical company
- Pierre Fabre
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 December 2024